Impact of Treatment with Ustekinumab on Severe Infections in a Patient with Uncontrolled Psoriasis and Late-Onset Combined Primary Immunodeficiency: Case Report
A 35-year-old man with a late-onset combined immunodeficiency (LOCID) variant of common variable immunodeficiency, severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease was attended in the Regional Hospital of Presidente Prudente and HC-FMUSP, São Paulo, Brazil. Anti-IL-12/IL-23 (ustekin...
Main Authors: | Luiz Euribel Prestes-Carneiro, Marilda Aparecida Milanez Morgado de Abreu, Eduardo Vinicius Mendes Roncada, Diego Garcia Muchon, Fernanda Miranda Caliani, Dewton Moraes Vasconcelos |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-09-01
|
Series: | Pathogens |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-0817/12/9/1156 |
Similar Items
-
Late reaction to ustekinumab infusion
by: Marina Resener Morais, et al.
Published: (2013-09-01) -
Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience
by: Melis Gönülal, et al.
Published: (2023-12-01) -
Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry
by: Abby S. Van Voorhees, et al.
Published: (2021-11-01) -
Ustekinumab en psoriasis cutánea y artritis psoriásica
by: Javier E. Rosa, et al.
Published: (2015-06-01) -
Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020-05-01)